Nyxoah Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Nyxoah şirketinin toplam hissedar öz sermayesi €104.7M ve toplam borcu €19.5M olup, bu da borç-öz sermaye oranını 18.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €142.8M ve €38.1M dir.

Anahtar bilgiler

18.7%

Borç/özkaynak oranı

€19.54m

Borç

Faiz karşılama oranı	n/a
Nakit	€70.98m
Eşitlik	€104.71m
Toplam yükümlülükler	€38.06m
Toplam varlıklar	€142.76m

Son finansal sağlık güncellemeleri

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24

Recent updates

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Dec 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NYXH 'nin kısa vadeli varlıkları ( €83.6M ) kısa vadeli yükümlülüklerini ( €15.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: NYXH şirketinin kısa vadeli varlıkları ( €83.6M ) uzun vadeli yükümlülüklerini ( €22.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NYXH şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: NYXH 'nin borç/öz sermaye oranı son 5 yılda 179.4% seviyesinden 18.7% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NYXH şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NYXH un, serbest nakit akışı her yıl % 30 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Nyxoah Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Nyxoah Deleted from Other OTC

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: €0.50 loss per share (vs €0.27 loss in 3Q 2023)

Nyxoah S.A. to Report Fiscal Year 2024 Results on Mar 13, 2025

Nyxoah S.A. Presents Dream U.S. Study Data At Isss 2024, Showing Significant Ahi Reduction and Quality-Of-Life Improvements

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

Price target decreased by 7.6% to €13.40

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

New minor risk - Shareholder dilution

Nyxoah S.A. has filed a Follow-on Equity Offering.

First quarter 2024 earnings released: €0.41 loss per share (vs €0.46 loss in 1Q 2023)

Full year 2023 earnings released: €1.51 loss per share (vs €1.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

New major risk - Share price stability

Price target decreased by 13% to €9.65

Nyxoah SA Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio(R)

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Revenue and earnings growth

New major risk - Financial position

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings released: €0.45 loss per share (vs €0.19 loss in 2Q 2022)

First quarter 2023 earnings released: €0.46 loss per share (vs €0.26 loss in 1Q 2022)

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Full year 2022 earnings released: €1.21 loss per share (vs €1.16 loss in FY 2021)

Nyxoah S.A. to Report Q3, 2023 Results on Nov 08, 2023

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Third quarter 2022 earnings released: €0.24 loss per share (vs €0.29 loss in 3Q 2021)

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Second quarter 2022 earnings released: €0.19 loss per share (vs €0.31 loss in 2Q 2021)

Nyxoah S.A. Announces CE Mark Approval for Genio® 2.1

Nyxoah SA Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

Nyxoah S.A. Announces U.S. Food and Drug Administration Approved the Use of Nyxoah's Next Generation Genio 2.1 System

Nyxoah S.A. Announces Board Changes

Nyxoah S.A. to Report First Half, 2022 Results on Aug 09, 2022

Nyxoah S.A. to Report Fiscal Year 2021 Results on Mar 24, 2022

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Deleted from Other OTC

Nyxoah SA's BETTER SLEEP Trial Reaches its Primary Endpoints

New 90-day high: €19.90

Nyxoah Receives FDA Approval for Full-Body 1.5T and 3T MRI Compatibility for the Genio System to Treat Obstructive Sleep Apnea

New 90-day high: €18.50

Nyxoah S.A. Announces First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio System for the Treatment of Obstructive Sleep Apnea

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Nyxoah S.A. Announces First Patient Implanted in the Dream US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea

Nyxoah S.A. has filed an IPO in the amount of €75.67805 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin